The Diagnostics and Health Tech business Scout will receive up to $1 million USD from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to provide proof-of-concept and feasibility prior to developing STI Scout, a new point-of-care test.
The test will identify and distinguish between Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (Ng). According to CARB-X officials, STI Scout is rapid and affordable, with a 30-minute response time and expected expenses that are less than half of the alternatives.
Furthermore, STI Scout can be used easily, and future tests will be able to use antibiotic susceptibility to advise a therapy for gonorrhoea treatment. The mobile app Scout Connect, which tracks outcomes, gives instructions and eventually enables users to communicate digitally with a healthcare provider, is used by STI Scout in conjunction with the Scout Hub.
Using their patented loop-de-loop chemistry, Scout is utilizing an isothermal technology that has been validated for highly accurate SARS-CoV-2 detection with their system. The technology is currently pending FDA Emergency Use Authorization for use in over-the-counter (OTC) settings and for point-of-care settings.
Cam Ball, PhD, Scout CTO, and Co-founder, said, “Our goal is to improve access to accurate diagnostics for everyone. Scout’s approach benefits clinicians and patients by providing timely, accurate results, which can lead to earlier diagnosis and treatment of patients. Importantly, Scout also could assist healthcare providers in determining which treatments are appropriate for the patient and can assist combating the spread of antibiotic resistance bacteria.”
Scout will be able to provide easy-to-use point-of-care testing at STI clinics and urgent care facilities, as well as the potential to offer an at-home STI test in the future.
For more details : https://euroinsightscare.com/
